CCWYF (SoftMedX Healthcare) 3-Year EBITDA Growth Rate: 87.70% (As of Jun. 2026) — 101% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CCWYF SoftMedX Healthcare Ltd CCWYF
54 GF Score
Price $0.70
GF Value $2.99
! 4 Warning Signs
View Full Analysis

What is SoftMedX Healthcare 3-Year EBITDA Growth Rate?

SoftMedX Healthcare CCWYF 54 3-Year EBITDA Growth Rate is 87.70% as of Jun. 2026, which is 101% above its 10-year median of 43.60. GuruFocus rates CCWYF with a GF Score™ of 54/100 and a GF Value™ of $2.99. The stock has 4 warning signs investors should review. Among 526 Healthcare Providers & Services companies, SoftMedX Healthcare ranks better than 98.29% on this metric.

SoftMedX Healthcare's EBITDA per Share for the six months ended in Jun. 2026 was $0.01.

During the past 12 months, SoftMedX Healthcare's average EBITDA Per Share Growth Rate was -99.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 87.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of SoftMedX Healthcare was 87.70% per year. The lowest was -152.80% per year. And the median was 43.60% per year.


SoftMedX Healthcare  (OTCPK:CCWYF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


SoftMedX Healthcare 3-Year EBITDA Growth Rate Related Terms


CCWYF vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison

For the Medical Care Facilities subindustry, SoftMedX Healthcare's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SoftMedX Healthcare 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SoftMedX Healthcare's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where SoftMedX Healthcare's 3-Year EBITDA Growth Rate falls into.


CCWYF
54GF Score
SoftMedX Healthcare Ltd CCWYF
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SoftMedX Healthcare 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 87.70% mean?
SoftMedX Healthcare (CCWYF) has a 3-Year EBITDA Growth Rate of 87.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SoftMedX Healthcare and its competitors. This is 101% above median its historical median of 43.60. According to the industry distribution chart, SoftMedX Healthcare ranks #9 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 1.7%.
Is SoftMedX Healthcare's 3-Year EBITDA Growth Rate too high?
SoftMedX Healthcare's current 3-Year EBITDA Growth Rate of 87.70% is 101% above median its 10-year median of 43.60. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.05. SoftMedX Healthcare's value of 87.70% is 772.6% above this industry median. Based on the distribution chart, SoftMedX Healthcare ranks #9 out of 526 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, SoftMedX Healthcare has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does SoftMedX Healthcare's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, SoftMedX Healthcare ranks #9 out of 526 companies for 3-Year EBITDA Growth Rate. This places SoftMedX Healthcare in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.05. SoftMedX Healthcare's value of 87.70% is 772.6% above this benchmark. While the company's 10-year median is 43.60 vs. the industry median of 10.05, SoftMedX Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SoftMedX Healthcare's current 3-Year EBITDA Growth Rate of 87.70% is 772.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SoftMedX Healthcare and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SoftMedX Healthcare's current 3-Year EBITDA Growth Rate is 87.70%, which is 101% above median its own 10-year median of 43.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SoftMedX Healthcare stock overvalued right now?
SoftMedX Healthcare (CCWYF) has a current 3-Year EBITDA Growth Rate of 87.70%. The stock's GF Value™ is $2.99, compared to a current price of $0.70 — trading 76.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 87.70%, which is 101% above median its 10-year median of 43.60 and 772.6% above the Healthcare Providers & Services industry median of 10.05. SoftMedX Healthcare's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For SoftMedX Healthcare (CCWYF), the current 3-Year EBITDA Growth Rate is 87.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SoftMedX Healthcare (CCWYF) Overvalued in 2026?

Based on GuruFocus' analysis, SoftMedX Healthcare stock appears to be undervalued. The current stock price of $0.70 is trading 76.6% below its estimated GF Value™ of $2.99.

Key valuation signals for CCWYF:

  • 3-Year EBITDA Growth Rate: 87.70% (101% above median its 10-year median of 43.60)
  • GF Value™: $2.99 vs. price of $0.70 (76.6% below fair value)
  • GF Score™: 54/100 with 4 warning signs
  • Industry Position: 772.6% above the Healthcare Providers & Services median (#9 of 526)

No single metric tells the full story. See the CCWYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SoftMedX Healthcare Business Description

Other Exchanges 00648:Hong Kong
Address 8-12 Hennessy Road, 8th Floor, China Hong Kong Tower, Wanchai, Hong Kong, HKG
SoftMedX Healthcare Ltd is principally engaged in the distribution of medical and healthcare equipment and products. The Group has one reportable operating segment: medical and well-being business, for the Distribution of medical and healthcare equipment and products.
54GF Score

Get the complete analysis for CCWYF

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price
$2.99
GF Value